Bank of New York Mellon Corp Cuts Position in Ralliant Corporation $RAL

Bank of New York Mellon Corp lowered its holdings in Ralliant Corporation (NYSE:RAL) by 1.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 628,201 shares of the company’s stock after selling 12,281 shares during the quarter. Bank of New York Mellon Corp owned 0.56% of Ralliant worth $26,127,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. Principal Financial Group Inc. increased its holdings in shares of Ralliant by 2.0% in the 1st quarter. Principal Financial Group Inc. now owns 546,560 shares of the company’s stock valued at $22,731,000 after purchasing an additional 10,592 shares in the last quarter. Fifth Third Bancorp grew its holdings in shares of Ralliant by 3,988.0% in the 1st quarter. Fifth Third Bancorp now owns 32,132 shares of the company’s stock worth $1,336,000 after acquiring an additional 31,346 shares during the period. Moran Wealth Management LLC acquired a new stake in shares of Ralliant in the 1st quarter worth approximately $227,000. Counterpoint Mutual Funds LLC purchased a new position in Ralliant in the 1st quarter valued at approximately $855,000. Finally, Canoe Financial LP increased its stake in Ralliant by 6.6% in the 1st quarter. Canoe Financial LP now owns 118,622 shares of the company’s stock valued at $4,933,000 after purchasing an additional 7,319 shares in the last quarter.

Ralliant Price Performance

RAL stock opened at $69.75 on Tuesday. The stock has a market capitalization of $7.81 billion and a price-to-earnings ratio of -6.38. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $75.41. The stock’s fifty day simple moving average is $66.65 and its 200-day simple moving average is $53.94.

Ralliant (NYSE:RAL) last released its earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm had revenue of $534.60 million during the quarter. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities research analysts expect that Ralliant Corporation will post 2.64 EPS for the current year.

Ralliant Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were given a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is currently -1.83%.

Analysts Set New Price Targets

A number of analysts have commented on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Royal Bank Of Canada raised their price target on Ralliant from $64.00 to $71.00 and gave the company a “sector perform” rating in a research report on Thursday, July 16th. Truist Financial reaffirmed a “buy” rating and set a $68.00 price target (up from $53.00) on shares of Ralliant in a research note on Wednesday, May 13th. Citigroup boosted their price objective on shares of Ralliant from $70.00 to $81.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Evercore initiated coverage on shares of Ralliant in a research report on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $73.00.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.